CHICAGO & ZUG, Switzerland–(BUSINESS WIRE)–The Amrize (NYSE: AMRZ) Board of Directors has appointed Mario Gross as President, Building Envelope, effective September 11, 2026. Gross succeeds Jake Gosa, who is stepping down from the role and is committed to a smooth transition. Gross has been a member of Amrize’s Executive Committee as its Chief Supply Chain Officer since the company’s listing on the NYSE in June 2025. He previously served as Chief Operating Officer of the Building Envelope bus
Month: September 2026
NEW YORK–(BUSINESS WIRE)–Blackstone Liquid Credit Strategies LLC, an affiliate of Blackstone Alternative Credit Advisors LP (collectively, and together with their affiliates in the credit-focused business of Blackstone, Inc., “Blackstone Credit & Insurance”), announced monthly distributions for the three listed closed-end funds it advises, Blackstone Senior Floating Rate 2027 Term Fund (NYSE: BSL), Blackstone Long-Short Credit Income Fund (NYSE: BGX), and Blackstone Strategic Credit 2027
IRVINE, Calif.–(BUSINESS WIRE)– #AHR–American Healthcare REIT, Inc. (NYSE: AHR) (“Company”) announced today that Jeff Hanson, the Company’s Chairman and Chief Executive Officer, Gabe Willhite, the Company’s President and Chief Operating Officer, and Alan Peterson, the Company’s Vice President of Investor Relations & Finance, will participate in a roundtable presentation at BofA Securities Global Real Estate Conference on Tuesday, September 15, 2026, at 12:45 p.m. to 1:20 p.m. Eastern Time. A liv
NEW YORK–(BUSINESS WIRE)–DWS Municipal Income Trust (KTF) (the “Fund”) announced today its regular September monthly distribution. Details are as follows: Declaration – 09/11/2026 Ex-Date – 09/23/2026 Record – 09/23/2026 Payable – 09/30/2026 Fund Ticker Distribution Per Share Prior Distribution Per Share DWS Municipal Income Trust KTF $0.0610 $0.0610 The Fund intends to distribute all or substantially all of its net investment income each year through its regular monthly distributions and
SAN MATEO, Calif.–(BUSINESS WIRE)–Essex Property Trust, Inc. (NYSE:ESS) announced today that Angela L. Kleiman, President and CEO, will be participating in a roundtable presentation at the 2026 Bank of America Global Real Estate Conference on Wednesday, September 16, 2026 at 10:20 a.m. Eastern Time. To listen to the panel, please visit the webcast link under the latest events section of the Company’s Investors website at www.essex.com. An archive of the webcast will be available for thirty da
SAN MATEO, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — Oportun Financial Corporation (“Oportun”, or the “Company”) today announced that, on September 10, 2026, in accordance with the offer letter agreement with Sean Rowles, the Company’s Chief Risk Officer, previously announced by the Company on June 16, 2026, it granted a long-term new hire equity award consisting of 382,653 restricted stock units representing the right to receive an equivalent number of shares of the Company’s common stock (“RSUs”) and 127,551 performance-vesting restricted stock units representing the right to receive an equivalent number of shares of the Company’s common stock at target (“PSUs”) to Mr. Rowles, effective on September 10, 2026. The RSUs and PSUs were an inducement material to Mr. Rowles entering into employment with the Company and granted under and subject to the terms of the Company’s Amended and Restated 2021 Inducement Equity Incentive Plan and applicable award agreements. The RSUs will vest as to one-third of the award on the one-year anniversary of the grant date and as to the remaining two-thirds of the award in eight substantially equal quarterly installments, such that the RSUs will be fully vested on the third anniversary of the grant date. The PSUs are eligible to vest after the end of the three-year performance period, based on a combination of performance goals and vesting terms. The vesting of the RSUs and PSUs is generally subject to Mr. Rowles remaining in continuous service with the Company through the relevant vesting dates. Mr. Rowles’s offer letter agreement was filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 18, 2026. The Amended and Restated 2021 Inducement Equity Incentive Plan and the forms of RSU and PSU award agreements are filed as exhibits to the Company’s Quarterly Report on Form 10-Q filed with the SEC on May 8, 2026.
About Oportun
Oportun (Nasdaq: OPRT) is a mission-driven financial services company that puts its members’ financial goals within reach. With intelligent borrowing, savings, and budgeting capabilities, Oportun empowers members with the confidence to build a better financial future. Since inception, Oportun has provided more than $22.7 billion in responsible and affordable credit, saved its members more than $2.5 billion in interest and fees, and helped its members set aside an average of more than $1,800 annually.
For more information, visit Oportun.com.
Investor Contact
Dorian Hare
(650) 590-4323
ir@oportun.com
Media Contact
Michael Azzano
Cosmo PR for Oportun
(415) 596-1978
michael@cosmo-pr.com
ATLANTA–(BUSINESS WIRE)–Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360, Compass’ investigational psilocybin treatment, if approved. Strata’s founders worked with Compass on the development of the provider traini
Antwerp, Belgium, September 11, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company’s Special and Extraordinary General Shareholders’ Meeting held on September 11, 2026. The approved resolutions included the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Company’s Board of Directors and the proposed consolidation and split adjustment of outstanding pre-Initial Public Offering (IPO) warrants.
“We are grateful for the support of our shareholders and excited to formally welcome Marino and Naimish to our Board,” said Tim Knotnerus, Chief Executive Officer of Agomab. “Both bring exceptional and complementary experience that will be highly valuable as we continue to advance our portfolio of potential disease-modifying therapies for fibro-inflammatory diseases. We look forward to benefiting from their perspectives as we work to create meaningful value for patients and shareholders alike.”
Marino Garcia commented, “I am honored to join Agomab’s Board at such an exciting stage in the Company’s development. Agomab has built a compelling pipeline targeting fibro-inflammatory diseases with significant unmet need, supported by a talented leadership team and strong scientific foundation. I look forward to working closely with the Board and management team to help advance the Company’s strategy and long-term vision.”
Naimish Patel, M.D., added, “I am delighted to join Agomab’s Board and contribute to the Company’s mission of developing innovative therapies for patients with fibro-inflammatory diseases. The combination of strong science, clear clinical focus and commitment to addressing significant unmet medical needs creates an exciting opportunity. I look forward to bringing my experience in translational medicine and clinical development to support Agomab’s continued progress.”
The Company also announced that shareholders approved the proposed consolidation and split adjustment of outstanding pre-IPO warrants, aligning such warrants with the share split implemented in connection with Agomab’s IPO in February 2026.
The materials relating to the Special and Extraordinary General Shareholders’ Meeting, including the biographies of the newly appointed Board members, are available on the Company’s website.
About Agomab
Agomab is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for fibro-inflammatory diseases with high unmet medical need. Agomab’s product candidates are designed to target established, potent pathways and utilize organ-restricted approaches, with the aim of increasing efficacy while minimizing safety liabilities. Fostering a culture of excellence, Agomab’s mission is to pioneer therapeutics that aim to resolve fibro-inflammation and restore organ function to enable people with these disorders to live fuller and healthier lives.
Cautionary Note regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “continue,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Such forward-looking statements include, but are not limited to, express and implied statements regarding the anticipated contributions of Marino Garcia and Naimish Patel, M.D. to the Company’s Board of Directors, the Company’s strategy and long-term vision, and the continued advancement of our portfolio of potential disease-modifying therapies for fibro-inflammatory diseases. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those expressed or implied by these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. These risks and uncertainties include, among others, the cost, timing and results of preclinical studies and clinical trials and other development activities by us and our collaborative partners; the likelihood of our preclinical and clinical programs being initiated and executed on timelines provided and reliance on our contract research organizations; our reliance on contract manufacturers to supply materials for research and development and the risk of supply interruption from a contract manufacturer; the potential for future data to alter initial and preliminary results of early-stage clinical trials; the unpredictability of the duration and results of the regulatory review of applications or clearances that are necessary to advance our clinical programs; the ability to secure, maintain and realize the intended benefits of collaborations with partners; the possible impairment of, inability to obtain, and costs to obtain intellectual property rights; possible safety or efficacy concerns that could emerge as new data are generated in research and development; general business, operational, financial and accounting risks, and risks related to litigation and disputes with third parties; and risks related to macroeconomic conditions and market volatility resulting from global economic developments, geopolitical instability and conflicts. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
Contacts
Investors
Sofie Van Gijsel
VP of Investor Relations
E-Mail: sofie.vangijsel@agomab.com
Phone: +1 781 296 1143
Media
Gretchen Schweitzer
Trophic Communications
E-Mail: agomab@trophic.eu
Phone: +49 172 861 8540
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
CONTACT: Contacts: Media: Jenn Gordon dna Communications Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Strategic Finance Investor.Relations@4DMT.com
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) — Impact BioMedical Inc. (the “Company”) today announced that the Company’s Board of Directors has approved a 1 for 12.62 reverse stock split of the Company’s issued and outstanding common stock, par value $0.001 per share (the “Common Stock“). The reverse stock split will become effective at 12:01 a.m., Eastern Time, on September 23, 2026. Starting with the opening of trading on that date, the Company’s Common Stock will continue to trade on the NYSE American Exchange under the ticker symbol “IBO” and will trade under a new CUSIP number to be assigned in connection with the reverse stock split.
On December 30, 2025, the Company’s stockholders approved a second reverse stock split of the Company’s Common Stock at a ratio of not less than 1-for-12.48 and not more than 1-for-50 to be implemented at the discretion of the Chief Executive Officer. The Reverse Stock Split is intended to support the Company’s efforts in connection with the proposed business-combination transaction and its continued-listing objectives. The Reverse Stock Split does not assure that the Company will satisfy applicable NYSE American continued-listing standards, obtain approval of any applicable listing application, or complete the proposed transaction.
The merger of Impact BioMedical Inc. and Zoar Ltd, upon approval, will result in a new company with manufacturing and clinical development expertise across a broad spectrum of active pharmaceutical ingredients (API’s) and intermediates for life-saving drugs worldwide, with immediate focus on emerging markets. It will also include significant intellectual property with potential in human health and wellness markets.
( Read the original merger announcement here.).
Upon completion of the proposed merger, Impact stockholders are expected to receive one (1) share of Zoar Ltd. for every four (4) shares of Impact Common Stock held immediately prior to the effective time of the merger, after giving effect to the Reverse Stock Split.
The reverse stock split will combine every 12.62 shares of the Company’s issued and outstanding Common Stock into one (1) new share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive a fractional share will have their fractional share rounded up to the next whole share. Other than adjustments resulting from the treatment of fractional shares, the Reverse Stock Split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company.
Stockholders holding shares in book-entry form or through a bank, broker, or other nominee do not need to take any action. Impact BioMedical’s transfer agent, Equiniti Trust Company, LLC (“Equiniti”), will manage the exchange. Stockholders of record who hold physical certificates will receive a letter of transmittal from Equiniti with instructions for exchanging their shares. Unless a stockholder specifically requests new paper certificates (or holds restricted shares), new shares will be issued electronically in book-entry form.
Following the reverse stock split, the total number of shares of Common Stock outstanding is expected to decrease from approximately 107,821,231 to 8,543,679 subject to minor adjustments due to rounding. Corresponding proportional adjustments will also be made to:
- Outstanding equity awards and related exercise prices
- Shares available under equity incentive plans
- Other relevant share-based agreements
The reverse stock split will not affect the total number of authorized shares, and all resulting shares will remain fully paid and non-assessable.
Additional information about the reverse stock split can be found in the Company’s definitive information statement filed with the Securities and Exchange Commission (the “SEC“) on December 30, 2025, which is available free of charge at the SEC’s website, www.sec.gov.
About Zoar Ltd.
Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.
About IBO:
Impact BioMedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.
Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date.
Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com
